A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease

Background: COVID-19 disease is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). In the first half of 2020 COVID-19 disease has already converted into a global pandemic. Many treatment options were explored through the world. Aims and Objectives: To compare the efficacy an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Praveen B Gautam, Arunesh Kumar, Babu Lal Kannojia, Rajendra Chaudhary
Formato:	article
Lenguaje:	EN
Publicado:	Manipal College of Medical Sciences, Pokhara 2021
Materias:	covid-19 disease dexamethasone methylprednisolone Medicine R
Acceso en línea:	https://doi.org/10.3126/ajms.v12i12.39294 https://doaj.org/article/b382186b54ce44858a71abb5ff45010a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b382186b54ce44858a71abb5ff45010a
record_format	dspace
spelling	oai:doaj.org-article:b382186b54ce44858a71abb5ff45010a2021-12-01T11:39:05ZA comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 diseasehttps://doi.org/10.3126/ajms.v12i12.392942467-91002091-0576https://doaj.org/article/b382186b54ce44858a71abb5ff45010a2021-12-01T00:00:00Zhttps://www.nepjol.info/index.php/AJMS/article/view/39294https://doaj.org/toc/2467-9100https://doaj.org/toc/2091-0576Background: COVID-19 disease is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). In the first half of 2020 COVID-19 disease has already converted into a global pandemic. Many treatment options were explored through the world. Aims and Objectives: To compare the efficacy and outcome of methylprednisolone (MTP) and dexamethasone (DEXA) in moderate-to-severe COVID-19 disease. Materials and Methods: In this prospective study, a total of 140 moderate to severe COVID-19 patients were enrolled from 15 April to June 15, 2021. These patients were randomly allocated into two groups, 70 patients were received MTP 2 mg/kg/day for 3 days followed by 1.0 mg/kg/day for 3 days in divided doses while 70 patients received DEXA 8 mg/day in divided dose up to 10 days. Results: The mean age was 45.5 years in MTP group whereas 45.34 years in DEXA group. The clinical outcome in MTP group and DEXA group was assessed in terms of clinical improvement (92.85% vs. 81.42%), radiological improvement (82.85% vs. 68.57%), transfer to ICU (5.71 vs. 14.57%), needs of ventilatory support (2.85% vs. 8.57%) and mortality (7.14% vs. 18.57%) respectively. Conclusion: In this study, MTP demonstrated better outcome as compared to DEXA in COVID-19 patients.Praveen B GautamArunesh Kumar Babu Lal Kannojia Rajendra Chaudhary Manipal College of Medical Sciences, Pokharaarticlecovid-19 diseasedexamethasonemethylprednisoloneMedicineRENAsian Journal of Medical Sciences, Vol 12, Iss 12, Pp 17-22 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 disease dexamethasone methylprednisolone Medicine R
spellingShingle	covid-19 disease dexamethasone methylprednisolone Medicine R Praveen B Gautam Arunesh Kumar Babu Lal Kannojia Rajendra Chaudhary A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
description	Background: COVID-19 disease is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). In the first half of 2020 COVID-19 disease has already converted into a global pandemic. Many treatment options were explored through the world. Aims and Objectives: To compare the efficacy and outcome of methylprednisolone (MTP) and dexamethasone (DEXA) in moderate-to-severe COVID-19 disease. Materials and Methods: In this prospective study, a total of 140 moderate to severe COVID-19 patients were enrolled from 15 April to June 15, 2021. These patients were randomly allocated into two groups, 70 patients were received MTP 2 mg/kg/day for 3 days followed by 1.0 mg/kg/day for 3 days in divided doses while 70 patients received DEXA 8 mg/day in divided dose up to 10 days. Results: The mean age was 45.5 years in MTP group whereas 45.34 years in DEXA group. The clinical outcome in MTP group and DEXA group was assessed in terms of clinical improvement (92.85% vs. 81.42%), radiological improvement (82.85% vs. 68.57%), transfer to ICU (5.71 vs. 14.57%), needs of ventilatory support (2.85% vs. 8.57%) and mortality (7.14% vs. 18.57%) respectively. Conclusion: In this study, MTP demonstrated better outcome as compared to DEXA in COVID-19 patients.
format	article
author	Praveen B Gautam Arunesh Kumar Babu Lal Kannojia Rajendra Chaudhary
author_facet	Praveen B Gautam Arunesh Kumar Babu Lal Kannojia Rajendra Chaudhary
author_sort	Praveen B Gautam
title	A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
title_short	A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
title_full	A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
title_fullStr	A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
title_full_unstemmed	A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
title_sort	comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe covid-19 disease
publisher	Manipal College of Medical Sciences, Pokhara
publishDate	2021
url	https://doi.org/10.3126/ajms.v12i12.39294 https://doaj.org/article/b382186b54ce44858a71abb5ff45010a
work_keys_str_mv	AT praveenbgautam acomparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT aruneshkumar acomparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT babulalkannojia acomparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT rajendrachaudhary acomparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT praveenbgautam comparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT aruneshkumar comparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT babulalkannojia comparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease AT rajendrachaudhary comparativestudyoftheefficacyandoutcomeofmethylprednisoloneanddexamethasoneinmoderatetoseverecovid19disease
_version_	1718405252691001344

A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease

Ejemplares similares